HomeCompareGSSRF vs MRK

GSSRF vs MRK: Dividend Comparison 2026

GSSRF yields 11111.11% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSSRF wins by $155845322245618304.00M in total portfolio value
10 years
GSSRF
GSSRF
● Live price
11111.11%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$155845322245618304.00M
Annual income
$153,134,179,268,263,440,000,000.00
Full GSSRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — GSSRF vs MRK

📍 GSSRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSSRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSSRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GSSRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSSRF
Annual income on $10K today (after 15% tax)
$944,444.44/yr
After 10yr DRIP, annual income (after tax)
$130,164,052,378,023,920,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, GSSRF beats the other by $130,164,052,378,023,920,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSSRF + MRK for your $10,000?

GSSRF: 50%MRK: 50%
100% MRK50/50100% GSSRF
Portfolio after 10yr
$77922661122809152.00M
Annual income
$76,567,089,634,131,720,000,000.00/yr
Blended yield
98.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GSSRF
No analyst data
Altman Z
-35.8
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSSRF buys
0
MRK buys
0
No recent congressional trades found for GSSRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSSRFMRK
Forward yield11111.11%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$155845322245618304.00M$56.8K
Annual income after 10y$153,134,179,268,263,440,000,000.00$9,798.13
Total dividends collected$155665220770885760.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GSSRF vs MRK ($10,000, DRIP)

YearGSSRF PortfolioGSSRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,121,811$1,111,111.11$11,206$366.19+$1.11MGSSRF
2$117,691,627$116,491,288.80$12,650$502.35+$117.68MGSSRF
3$11,547,755,012$11,421,824,971.17$14,407$694.19+$11547.74MGSSRF
4$1,059,734,753,299$1,047,378,655,436.53$16,585$967.82+$1059734.74MGSSRF
5$90,963,535,000,723$89,829,618,814,692.62$19,342$1,363.89+$90963534.98MGSSRF
6$7,303,524,681,616,793$7,206,193,699,166,020.00$22,913$1,947.19+$7303524681.59MGSSRF
7$548,553,313,414,587,650$540,738,542,005,257,700.00$27,662$2,823.89+$548553313414.56MGSSRF
8$38,543,778,083,006,005,000$37,956,826,037,652,400,000.00$34,159$4,173.35+$38543778083005.97MGSSRF
9$2,533,778,483,509,246,600,000$2,492,536,640,960,430,300,000.00$43,337$6,308.80+$2533778483509246.50MGSSRF
10$155,845,322,245,618,300,000,000$153,134,179,268,263,440,000,000.00$56,776$9,798.13+$155845322245618304.00MGSSRF

GSSRF vs MRK: Complete Analysis 2026

GSSRFStock

Gossan Resources Limited, an exploration and evaluation stage company, engages in the acquisition, exploration, and development of resource properties in Canada. It holds interest in the Glitter property located in the sturgeon lake greenstone belt of northwestern Ontario; the Gander Gold property covers an area of 8,875 hectares situated in Newfoundland; and the Weir Pond project covers an area of 975 hectares and the Island Pond properties cover an area of 1,050 hectares located in Newfoundland. The company also owns interests in a portfolio of properties hosting gold, platinum group, and base metals, as well as specialty green battery metals, vanadium, titanium, tantalum, lithium, dolomite, and chromium. In addition, it holds production royalty interests in a high-purity silica sand deposit. Gossan Resources Limited was incorporated in 1980 and is headquartered in Winnipeg, Canada.

Full GSSRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GSSRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSSRF vs SCHDGSSRF vs JEPIGSSRF vs OGSSRF vs KOGSSRF vs MAINGSSRF vs JNJGSSRF vs ABBVGSSRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.